Aim: Development of EGF-liposomes (LP-EGF) for selective molecules delivery in tumors expressing EGFR.
Material & methods: In vitro cellular interaction of EGF-LP and nontargeted liposomes (LP-N) was assayed at 37 and 4°C in cells expressing different EGFR levels. Receptor-mediated uptake was investigated by competition with a monoclonal antibody anti-EGFR. Selective intracellular drug delivery and efficacy was tested by oxaliplatin encapsulation. In vivo biodistribution of LP-N and LP-EGF was done in xenograft model.
Results: LP-EGF was internalized by an active and selective mechanism through EGFR without receptor activation. Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+. LP-EGF was accumulated in tumor over 72 h postdosing, while LP-N in spleen.
Conclusion: LP-EGF represents an attractive nanosystem for cancer therapy or diagnosis.

cetuximab, colorectal cancer, EGF, EGFR, oxaliplatin, targeted liposomes
dx.doi.org/10.2217/nnm.15.208, hdl.handle.net/1765/86001
Nanomedicine
No subscription
Department of Surgery

Zalba, S, Contreras, A.M, Merino, M, Navarro, I, De Ilarduya, C.T, Trocóniz, I.F, … Garrido, M.J. (2016). EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model. Nanomedicine, 11(5), 465–477. doi:10.2217/nnm.15.208